Efficacy of Topical Ivermectin for the Treatment of Cutaneous and Ocular Rosacea
- 18 August 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Ocular Immunology and Inflammation
- Vol. 29 (6), 1137-1141
- https://doi.org/10.1080/09273948.2020.1727531
Abstract
Purpose: To investigate the efficacy of once-daily topical treatment of ocular and cutaneous rosacea with ivermectin 1% cream (Soolantra (R), Galderma). Methods: Ten patients with rosacea were evaluated in a retrospective monocentric pilot study. Subjective symptoms (measured with the Ocular Surface Disease Index), skin findings, and ocular changes (blepharitis with telangiectasia and meibomian gland dysfunction, conjunctival redness, tear breakup time (TBUT), and fluorescein staining of the cornea) were evaluated. The follow-up was 8 months (range: 5-12 months). Results: The OSDI score decreased in the 8th week of treatment (38.5 +/- 21.7, P = .004). After 16 weeks, blepharitis (P = .004), and conjunctival redness (P = .008) had strongly improved, and grade 1 was seen in all patients until the end of follow-up. Fluorescein staining of the cornea (P = .001) and TBUT (P = .016) showed significant improvement until the last follow-up visit. No side effects were observed. Conclusion: Topical ivermectin cream 1% given daily is an effective and safe therapy against rosacea.This publication has 30 references indexed in Scilit:
- Clinical Treatment of Ocular Demodex folliculorum by Systemic IvermectinAmerican Journal of Ophthalmology, 2011
- The International Workshop on Meibomian Gland Dysfunction: Report of the Diagnosis SubcommitteeInvestigative Ophthalmology & Visual Science, 2011
- Chitin Modulates Innate Immune Responses of KeratinocytesPLOS ONE, 2011
- RosaceaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009
- Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophilsBritish Journal of Dermatology, 2007
- Increased serine protease activity and cathelicidin promotes skin inflammation in rosaceaNature Medicine, 2007
- Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosaceaJournal of the American Academy of Dermatology, 2007
- Ocular Rosacea Can Mimic TrachomaCornea, 2004
- Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosaceaJournal of the American Academy of Dermatology, 2004
- The Prevalence of Ocular Signs in Acne RosaceaCornea, 2003